The proportion of the TOX+ Treg subgroup is increased in patients with non-Hodgkin’s lymphoma (22), multiple myeloma (MM) (21), or de novo AML (18), and this phenomenon results in Treg activation instead of Treg exaustion. This evidence concerns the gene TOX and non-Hodgkin lymphoma.